BTK and B-cell chronic lymphocytic leukemia: One of the most common on-target resistance mechanisms to BTK directed therapies is the acquisition of genomic variants within the CLL cell which alter the amino acid sequence of the BTK protein and affect the binding/activity of various BTK directed therapies.